Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | C5 | P01031 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236844 | 0.84 | PKM (0.55) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4683708 | 0.84 | PKM (0.63) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL5149842 | 0.84 | PKM (0.63) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4226971 | 0.84 | PKM (0.60) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4228811 | 0.84 | PKM (0.60) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4233456 | 0.84 | PKM (0.63) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| Ammonia Solution, Strong SCHEMBL4235457 | 0.83 | PKM (0.58) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4236386 | 0.83 | PKM (0.53) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4237344 | 0.82 | PKM (0.58) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A | |
| SCHEMBL4229112 | 0.82 | PKM (0.57) | PKMTAS1R3TAS1R1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.